A Multicenter, Single-arm, Prospective Study to Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
The goal of this prospective study is to learn whether there is a synergistic effect when radiotherapy is combined with ripretinib in the treatment of patients with unresectable advanced GIST. It will also learn about the safety of this regimen.The main questions it aim to answer is: Dose radiotherapy combined with ripretinib prolong the time to disease progression for patients with advanced GIST?
• Voluntary participation and signed informed consent;
• age: 18 to 75 years, Male or female
• Patients with histologically confirmed GIST and Imaging evaluated as unresectable recurrent and metastatic disease or locally advanced.
• ECOG Performance Score: 0-2
• Subjects who have progressed or documented intolerance after previous first-line, second-line, and third-line treatments.
• At least one measurable lesion in the abdominal or pelvic cavity that has progressed after frontline treatment
• Adequate organ function and bone marrow reserve